BPC-157: What the Research Actually Shows (and What It Doesn't)

BPC-157 is a synthetic 15-amino-acid peptide based on a fragment of a protein first isolated from gastric juice. Almost all of the research behind it comes from animals and cells: a 2025 systematic review found 36 relevant studies, 35 preclinical and 1 clinical. It is not FDA approved, human data are limited to a few small studies, and its safety in people is not established.

A plain note first: this is general information, not medical advice. Nothing here is a recommendation to use or avoid any substance, and this post deliberately contains no dosing, sourcing, or how-to information. If you are considering BPC-157 or already using it, talk to your doctor or pharmacist.

What BPC-157 is

BPC stands for "body protection compound." In its July 2026 briefing document, the FDA describes BPC-157 as "a pentadecapeptide fragment of the BPC protein originally isolated from human gastric juice," citing the original 1993 work by Sikirić and colleagues. A pentadecapeptide is simply a chain of 15 amino acids. A 2025 narrative review from the University of Utah calls it "a synthetic pentadecapeptide originally isolated from gastric juice."

So the word "natural" in marketing needs care. The sequence was identified from a stomach protein, but the product people discuss online is made in a lab. The FDA briefing also notes that BPC-157 was "first described in the literature in 1993" and was originally framed as "a possible endogenous free radical scavenger and organoprotection mediator."

There is no approved medicine containing it. The FDA states: "There is no approved product containing BPC-157-related BDSs in any country at this time," and it does not appear in the European, Japanese, or International Pharmacopeias.

Why it is trending

BPC-157 has moved from a niche research topic to something people ask about at the gym, mostly for injury recovery. You will not find a reliable count of how many people use it, and we are not going to guess at one. What the medical literature does say is qualitative.

A 2026 review in Sports Medicine describes peptide use in sports medicine as "rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement," and notes how social media amplifies the placebo effect around these products. A 2026 review in Missouri Medicine says injectable peptides "are increasingly used without prescriptions for cosmetic and athletic enhancement, driven by digital marketing and social media." The 2025 systematic review in HSS Journal adds that, despite lacking FDA approval and being banned in professional sports, "it is increasingly used by clinicians and athletes."

In short: the interest is real, and it is running well ahead of the evidence.

What the animal and cell studies show

This is where BPC-157 looks most promising, and it is worth being fair about that. The 2025 HSS Journal systematic review screened 544 articles published from 1993 to 2024 and included 36 studies. Of those, 35 were preclinical (animal or cell studies) and 1 was clinical. The authors report that "in preclinical models, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries."

On mechanism, the reviews describe effects on blood vessel growth (angiogenesis), growth factor signaling, and inflammation. The Utah review says BPC-157 "has demonstrated regenerative properties across numerous animal models" and calls the preclinical effects "robust."

The FDA's own read of the nonclinical data is more cautious. Its briefing acknowledges rat studies reporting that BPC-157 "could prevent colonic fistulas, hepatic lesions, and GI lesions," but adds that "dose-response relationships... have not been established, the molecular targets for BPC-157-related substances have not been identified, and the mechanisms of action... remain poorly understood." It also found that nonclinical toxicology studies "were also too limited in scope and duration to inform safety considerations," and that no carcinogenicity studies were submitted or identified.

Why animal results do not settle the question: rodents heal differently, studies are often small, and many effects seen in animals never replicate in people. The HSS Journal authors grade the whole evidence base as "level IV and level V studies," the lowest tiers of clinical evidence.

What human data exists

Very little. The Utah review puts it plainly: "Only three pilot studies have examined BPC-157 in humans," covering knee pain, interstitial cystitis, and a safety study. Here is what each abstract reports, without the dosing details.

Study	Design	People	What the abstract reports
Lee & Padgett, 2021	Retrospective chart review with phone survey, one clinic	16	11 of 12 who received BPC-157 alone reported significant knee pain improvement
Lee, Walker & Ayadi, 2024	Pilot study, no control group, one clinic	12	All 12 women with interstitial cystitis rated their treatment a success; no adverse events reported
Lee & Burgess, 2025	Safety pilot, one clinic	2	No measurable effects on tested heart, liver, kidney, thyroid, or glucose markers; no side effects reported

Read these with their limits in view. The knee study was retrospective, and its abstract states that "no specific tools were used to measure their improvement in function, quality of life, stiffness or activities of daily living." The interstitial cystitis study had no comparison group, so a placebo response cannot be separated from a drug effect. The safety pilot had two participants, both of whom had received BPC-157 before. None of these designs can show that BPC-157 works or that it is safe.

The FDA briefing adds two more small studies in healthy subjects or people with ulcerative colitis, lasting "a maximum of two weeks," where "no serious adverse events were reported" but "the authors provided limited information on safety and associated safety monitoring." The FDA also found adverse event reports in its FAERS database, including "injection site reaction, shortness of breath, and diffuse hyperpigmentation and gingival darkening," while noting "it is unclear whether these AEs were attributable to BPC-157."

The FDA's overall conclusion: "There is insufficient clinical safety information to characterize the safety profile of BPC-157." The HSS Journal review is just as direct: "No clinical safety data were found."

Regulatory status

FDA

BPC-157 is not an FDA-approved drug. The more confusing part is its status for compounding, which has changed over the past few years.

The FDA keeps a page of bulk drug substances that "may present significant safety risks" when nominated for use in compounding, known as category 2. BPC-157 was placed there. As of the page's April 22, 2026 update, BPC-157 appears under "Bulk drug substances nominated but withdrawn," described as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators." The FDA's concern text is still listed: "Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization... the agency lacks sufficient information to know whether the drug would cause harm when administered to humans."

The FDA then brought BPC-157 to its Pharmacy Compounding Advisory Committee on July 23, 2026, evaluated for ulcerative colitis. In its briefing, FDA staff proposed that BPC-157 "NOT be included on the 503A Bulks List," concluding that "a balancing of the criteria weighs against" it. ABC News reported that the committee voted 8 to 6 in favor of adding it, with one abstention, and that "the vote is non-binding and still needs sign-off from the FDA." As of October 5, 2026, we did not find a final FDA determination.

Sport

The FDA briefing states that "BPC-157 is listed on the World Anti-Doping Agency's prohibited list under the non-approved substances (S0) section." We could not load WADA's own site to confirm the current list directly, so if you compete in a tested sport, check the current Prohibited List and your federation's rules before taking anything.

Quality and sterility concerns

Because there is no approved product, what people actually buy varies. The FDA briefing notes that some websites offer BPC-157 labeled "for research purposes only and not for human or veterinary use." That label means the product is not made or checked as a medicine for people.

The FDA's concerns center on quality. It found that data on identity, purity, and quality "were either lacking or deemed to be inadequate," including testing for "peptide-related impurities and aggregates" and "microbial quality (bioburden, bacterial endotoxins)." It warns that "the stability, pharmacological activity, and immunogenic properties of peptides are highly sensitive to the manufacturing process," and that impurities or aggregates may be "capable of inducing untoward immunogenic responses," meaning unwanted immune reactions.

The Missouri Medicine review lists risks of unregulated peptides including "product contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis, carcinogenesis." The HSS Journal authors conclude that "adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety." For a broader look at the same issues with other trending compounds, see our explainer on retatrutide and research peptides.

What to ask a doctor

If BPC-157 has come up for you, a short conversation with your doctor or pharmacist is worth more than another forum thread. Useful questions:

• What is actually causing my pain or injury, and what are the proven treatments for it?
• Could anything I am taking, or any condition I have, interact with an unapproved substance?
• What does the evidence for this condition look like in humans, not animals?
• What are the risks of a product with no verified identity, purity, or sterility?
• If I compete in a tested sport, would this put my eligibility at risk?
• What signs would mean I should stop something and get seen right away?

The 2026 Sports Medicine review was written partly to give clinicians "a framework to navigate patient discussions about peptides," so raising it is a normal, reasonable thing to do. Be honest about what you are using. Your doctor cannot help with what they do not know about.

If your real goal is body composition

A lot of interest in BPC-157 sits next to a simpler goal: recover well, build muscle, lose fat. Those outcomes depend mostly on unglamorous basics with far stronger evidence: enough protein, consistent training, sleep, and knowing what you actually eat. Our guides on high-protein foods and how to track macros cover the practical side.

That last part, knowing what you eat, is where most people stall. Part of why I built Nouri: in my first tracker, logging a normal dinner took several minutes, and after a long day I just would not do it. Accuracy does not matter if you stop opening the app by week three. In Nouri, you can type a meal like a note, say it, snap a photo, or ask Siri from the lock screen, and get calories and macros with per-item reasoning you can check. Nouri does not treat anything and is not a medical tool. It just makes the basics easier to keep doing.

FAQ

What is BPC-157?

BPC-157 is a synthetic peptide of 15 amino acids based on a fragment of a protein first isolated from human gastric juice. BPC stands for "body protection compound." There is no approved medicine containing it in any country, according to the FDA.

Is BPC-157 FDA approved?

No. BPC-157 is not an FDA-approved drug. FDA staff proposed against adding it to the list of substances pharmacies may use in compounding, and while an advisory committee voted in favor in July 2026, that vote is non-binding and we found no final FDA decision as of October 5, 2026.

Does BPC-157 work in humans?

There is not enough human evidence to say. A 2025 systematic review found 35 preclinical studies and 1 clinical study, and a 2025 review counted only three small human pilot studies. None had a control group capable of separating a real effect from placebo.

Is BPC-157 safe?

Its safety in people has not been established. The FDA concluded there is "insufficient clinical safety information to characterize the safety profile of BPC-157," and raised concerns about immunogenicity, impurities, and product quality.

Is BPC-157 banned in sports?

The FDA's July 2026 briefing states that BPC-157 is on the World Anti-Doping Agency's prohibited list under non-approved substances (S0). Athletes in tested sports should check the current WADA list and their own federation's rules.

Why is BPC-157 so popular right now?

Recent medical reviews point to patient demand for faster injury recovery, plus digital marketing and social media. Popularity reflects interest, not proof: the human evidence remains very limited.

What does "research use only" mean on a peptide?

It means the seller is not presenting the product as made or tested for human use. The FDA has flagged gaps in data on identity, purity, impurities, and microbial quality for BPC-157, which is exactly what medical-grade manufacturing is meant to control.

What are the side effects of BPC-157?

Small human studies reported no adverse events, but they were too small and short to rule much out. The FDA found adverse event reports including injection site reaction, shortness of breath, and skin and gum darkening, though it was unclear whether BPC-157 caused them.

What is the easiest way to track protein and calories while focusing on the basics?

Use a tracker you will actually keep using. In Nouri, you log a meal by typing a sentence, speaking, taking a photo, or asking Siri, and see calories and protein against your targets right away. A weekly Nouri Report then shows how your week went and one thing to focus on next.

Bottom line

BPC-157 has an interesting animal and cell research record and very little human evidence: a handful of small, uncontrolled studies and no established safety profile. It is not FDA approved, FDA staff argued against allowing it in compounding, and product quality outside regulated channels is a real concern. If you are curious about it, bring it to your doctor. If your goal is body composition, start with protein, training, and tracking, using our guides to high-protein foods and macro tracking, and keep it simple with Nouri.

Sources

• Vasireddi N et al., "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS Journal, 2025, pubmed.ncbi.nlm.nih.gov/40756949 (checked October 5, 2026)
• McGuire FP et al., "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing," Current Reviews in Musculoskeletal Medicine, 2025, pubmed.ncbi.nlm.nih.gov/40789979 (checked October 5, 2026)
• Lee E, Padgett B, "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain," Alternative Therapies in Health and Medicine, 2021, pubmed.ncbi.nlm.nih.gov/34324435 (checked October 5, 2026)
• Lee E, Walker C, Ayadi B, "Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study," Alternative Therapies in Health and Medicine, 2024, pubmed.ncbi.nlm.nih.gov/39325560 (checked October 5, 2026)
• Lee E, Burgess K, "Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study," Alternative Therapies in Health and Medicine, 2025, pubmed.ncbi.nlm.nih.gov/40131143 (checked October 5, 2026)
• Mendias CL, Awan TM, "Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance," Sports Medicine, 2026, pubmed.ncbi.nlm.nih.gov/41966639 (checked October 5, 2026)
• Moiz A, O'Keefe EL, O'Keefe JH, "Dangers of Injectable Peptides and Other Unregulated 'Biohacking' Drugs," Missouri Medicine, 2026, pubmed.ncbi.nlm.nih.gov/42757290 (checked October 5, 2026)
• FDA, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of April 22, 2026), fda.gov (checked October 5, 2026)
• FDA, Pharmacy Compounding Advisory Committee, July 23-24, 2026 meeting page, fda.gov (checked October 5, 2026)
• FDA Briefing Document for BPC-157-Related Bulk Drug Substances, PCAC meeting July 23-24, 2026, fda.gov/media/193343/download (checked October 5, 2026)
• FDA Briefing Document Introduction, PCAC meeting July 23-24, 2026, fda.gov/media/193342/download (checked October 5, 2026)
• ABC News, "FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list," July 23, 2026, abcnews.com (checked October 5, 2026)